Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.39 |
| ▸ | TTR | P02766 | 2/20 | 0.39 |
| ▸ | ALB | P02768 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.36 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9491002 | 0.85 | TRPV4 (0.40) | CES2CES1TRPV4TTRALB | |
| SCHEMBL29891425 | 0.83 | GRM5 (0.43) | TRPV4TTRALBMEN1KMT2A | |
| SCHEMBL18002603 | 0.83 | TTR (0.41) | CES2CES1TRPV4TTRALB | |
| SCHEMBL20912550 | 0.83 | TTR (0.52) | CES2CES1TRPV4TTRALB | |
| SCHEMBL9224719 | 0.83 | EGLN2 (0.40) | TRPV4TTRALBMEN1KMT2A | |
| SCHEMBL23099521 | 0.83 | TTR (0.52) | CES2CES1TRPV4TTRALB | |
| SCHEMBL30297979 | 0.83 | TTR (0.52) | CES2CES1TRPV4TTRALB | |
| SCHEMBL8463144 | 0.83 | GRM5 (0.43) | TRPV4TTRALBMEN1KMT2A | |
| SCHEMBL6649045 | 0.80 | TRPV4 (0.61) | TRPV4TTRALBMEN1KMT2A | |
| SCHEMBL3171347 | 0.79 | KIF11 (0.49) | TRPV4KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 430 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118993958-A | Method for synthesizing polyfluoroaryl sulfide | 三峡大学 | 2024-11-22 | — | — | CN | claimed |
| US-8952083-B2 | Fluorocopolymer composition and its production process | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | claimed |
| CN-102531833-A | Preparation method of polyfluoroethane compound | SHANGHAI SINOFLUORO SCIENT CO | 2012-07-04 | — | — | CN | claimed |
| EP-4720044-A1 | AROMATIC AMIDES AND CONJUGATES THEREOF AS BINDERS TO TEAD | Beactica Therapeutics AB (SE) | 2026-04-08 | — | — | EP | disclosed |
| US-12472181-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2025-11-18 | — | — | US | disclosed |
| WO-2025137605-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF PROTO-ONCOGENE TYROSINE PROTEIN KINASE RECEPTOR | C4 THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-114423758-B | Antibacterial compounds | 爱尔兰詹森科学公司 | 2025-05-27 | — | — | CN | disclosed |
| US-12297322-B2 | Triazine-based membranes for gas separation | UT-BATTELLE, LLC (US) | 2025-05-13 | — | — | US | disclosed |
| WO-2025070482-A1 | COMPOUND, LIGHT-EMITTING MATERIAL, AND ORGANIC LIGHT-EMITTING ELEMENT | 株式会社Kyulux | 2025-04-03 | — | — | WO | disclosed |
| EP-3774786-B1 | METHOD FOR THE PREPARATION OF A 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONE | BAYER AG (DE) | 2024-12-25 | — | — | EP | disclosed |
| WO-2024240840-A1 | AROMATIC AMIDES AND CONJUGATES THEREOF AS BINDERS TO TEAD | BEACTICA THERAPEUTICS AB (SE) | 2024-11-28 | — | — | WO | disclosed |
| EP-0391591-B1 | Pyrimidine derivative and liquid crystal composition incorporating the same | SEIKO EPSON CORP (JP) | 1994-06-15 | — | — | EP | disclosed |
| EP-0387032-B1 | TRIFLUOROBENZENE DERIVATIVES AND LIQUID CRYSTAL COMPOSITIONS CONTAINING THE SAME | CHISSO CORP (JP) | 1993-06-16 | — | — | EP | disclosed |
| WO-1992018467-A1 | CYANOPHENOXYNAPHTHYL OXYCARBOXYLIC ACID DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 1992-10-29 | — | — | WO | disclosed |
| EP-0270964-B1 | PROCESS FOR OBTAINING SUBSTITUTED FLUOROBENZENES | BAYER AG (DE) | 1992-07-08 | — | — | EP | disclosed |
| US-5032313-A | Trifluorobenzene derivative and liquid crystal composition containing the same | CHISSO CORPORATION (JP) | 1991-07-16 | — | — | US | disclosed |
| EP-0391591-A2 | Pyrimidine derivative and liquid crystal composition incorporating the same | SEIKO EPSON CORPORATION (JP) | 1990-10-10 | — | — | EP | disclosed |
| EP-0387032-A1 | Trifluorobenzene derivatives and liquid crystal compositions containing the same | Chisso Corporation (JP) | 1990-09-12 | — | — | EP | disclosed |
| US-4868347-A | SOLVENT EXTRACTION | BAYER AKTIENGESELLSCHAFT (DE) | 1989-09-19 | — | — | US | disclosed |
| EP-0270964-A2 | Process for obtaining substituted fluorobenzenes | BAYER AG (DE) | 1988-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12472181-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | IL15, IL2, IL33 | CES2 3035/4885CES1 1544/4885TRPV4 3854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.